With the emergence of targeted therapies for various chronic inflammatory diseases, such as RA and OA, focusing on the CCL2/CCR2 axis and its clinical implications can offer new perspectives on how to manage these common and debilitating joint diseases (Figure 2). This evidence concerns the gene CCL2 and arthropathy.